GH Research PLC (NASDAQ:GHRS) Given Average Recommendation of "Moderate Buy" by Brokerages

Shares of GH Research PLC (NASDAQ:GHRS - Get Free Report) have been given a consensus rating of "Moderate Buy" by the eight research firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $32.00.

Several equities analysts recently issued reports on the company. Cantor Fitzgerald started coverage on GH Research in a research report on Wednesday, June 4th. They issued an "overweight" rating and a $25.00 target price on the stock. Wall Street Zen raised GH Research from a "sell" rating to a "hold" rating in a report on Saturday, July 5th. JMP Securities restated a "market outperform" rating and issued a $39.00 price objective on shares of GH Research in a research report on Tuesday, June 24th. Finally, Zacks Research lowered shares of GH Research from a "strong-buy" rating to a "hold" rating in a report on Wednesday, August 13th.

GH Research Stock Up 1.1%

Shares of GH Research stock opened at $13.48 on Tuesday. The firm has a market capitalization of $701.36 million, a P/E ratio of -18.22 and a beta of 0.97. GH Research has a 52 week low of $6.00 and a 52 week high of $20.50. The company has a 50 day moving average price of $13.77 and a 200 day moving average price of $12.27.

GH Research (NASDAQ:GHRS - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.07. As a group, research analysts anticipate that GH Research will post -0.8 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GH Research

Hedge funds have recently modified their holdings of the company. BNP Paribas Financial Markets acquired a new stake in shares of GH Research during the 4th quarter valued at about $44,000. Osaic Holdings Inc. grew its holdings in GH Research by 63.6% in the second quarter. Osaic Holdings Inc. now owns 6,175 shares of the company's stock valued at $75,000 after purchasing an additional 2,400 shares during the period. JPMorgan Chase & Co. purchased a new stake in shares of GH Research in the second quarter valued at approximately $79,000. Virtus Investment Advisers LLC purchased a new position in shares of GH Research during the 2nd quarter valued at approximately $89,000. Finally, Two Sigma Investments LP purchased a new stake in GH Research in the 4th quarter worth $117,000. 56.90% of the stock is owned by hedge funds and other institutional investors.

GH Research Company Profile

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.